Kura Oncology Inc 2025年季度报告

FORM10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period endedMarch 31,2025or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from ________ to ________Commission File Number:001-37620 KURA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware61-1547851(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.) 12730 High Bluff Drive,Suite 400,San Diego,CA92130(Address of principal executive offices)(Zip Code)(858)500-8800(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which registeredThe Nasdaq Global Select Market Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subjectto such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of the close of business on April 28, 2025, the registranthad86,574,687shares of Common Stock, $0.0001 par value, outstanding. KURA ONCOLOGY, INC.TABLE OF CONTENTS PART I. FINANCIAL INFORMATIONItem 1. Condensed Financial Statements (unaudited)Condensed Balance Sheets − As of March 31, 2025 (unaudited) and December 31, 20241Condensed Statements of Operations and Comprehensive Loss – Three Months Ended March 31, 2025 and 2024(unaudited)2Condensed Statements of Stockholders’ Equity – Three Months Ended March 31, 2025 and 2024 (unaudited)3Condensed Statements of Cash Flows – Three Months Ended March 31, 2025 and 2024 (unaudited)4Notes to Condensed Financial Statements (unaudited)5Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations16Item 3. Quantitative and Qualitative Disclosures about Market Risk26Item 4. Controls and Procedures27PART II. OTHER INFORMATIONItem 1. Legal Proceedings28Item 1A. Risk Factors28Item 6. Exhibits76Signatures KURA ONCOLOGY, INC.Condensed Balance Sheets(In thousands, except par value data) KURA ONCOLOGY, INC.Condensed Statements of Operations and Comprehensive Loss(In thousands, except per share data)(Unaudited) KURA ONCOLOGY, INC.Condensed Statements of Stockholders’ Equity(In thousands)(Unaudited) KURA ONCOLOGY, INC.Condensed Statements of Cash Flows(In thousands)(Unaudited) KURA ONCOLOGY, INC.Notes to Unaudited Condensed Financial Statements 1. Organization and Basis of Presentation Kura Oncology, Inc. is a clinical-stage biopharmaceutical company committed to realizing the promise of precisionmedicines for the treatment of cancer. Our pipeline consists of small molecule product candidates designed to target cancersignaling pathways where there is a strong scientific and clinical rationale to improve outcomes and, in general, we intend to pairour product candidates with molecular or cellular diagnostics to identify those patients most likely to respond to treatment. We areconducting clinical trials of three product candidates: ziftomenib, KO-2806 and tipifarnib. We also have additional programs thatare at a discovery stage. We plan to advance our product candidates through a combination of internal development and strategicpartnerships while maintaining significant development and commercial rights. References in these Notes to Unaudited Condensed Financial Statements to the “Company,” “we,” “our” or “us,” refer toKura Oncology, Inc. Basis of Presentation The accompanying unaudited condensed financial statements should be read in conjunction with the audited financialstatements and notes thereto in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with theSecurities and Exchange Commission on February 28, 2025, from whic